Related Experiment Video

Updated: Aug 9, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

"Pill-in-Pocket" anticoagulation for stroke prevention in atrial fibrillation

Graham Peigh1, Rod S Passman1,2,3

  • 1Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Journal of Cardiovascular Electrophysiology
|February 22, 2023
PubMed

Insights

Uninterrupted anticoagulation for atrial fibrillation (AF) may pose risks and may not benefit all patients. A targeted approach, like "pill-in-the-pocket" therapy, is being investigated to optimize AF treatment.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Current practice favors uninterrupted anticoagulation for atrial fibrillation (AF), irrespective of AF burden, based on early trial data.
  • However, continuous anticoagulation carries risks and may not be universally beneficial for all AF patients.
  • Emerging data suggest a threshold for AF duration and a temporal link between stroke and prolonged AF episodes, necessitating a more tailored anticoagulation strategy.

Purpose of the Study:

  • To review evidence supporting the investigation of a "pill-in-the-pocket" anticoagulation strategy for AF.
  • To introduce the Rhythm Evaluation for Anticoagulation Therapy for Atrial Fibrillation (REACT-AF) trial, designed to rigorously assess this targeted approach.

Main Methods:

  • Review of contemporary data on AF burden, stroke association, and anticoagulation thresholds.
  • Introduction and description of the REACT-AF trial design and objectives.

Main Results:

  • Discussion of data supporting the potential efficacy and safety of intermittent anticoagulation for select AF patients.
  • Highlighting the critical role of the upcoming REACT-AF trial in providing robust evidence.

Conclusions:

  • A targeted anticoagulation approach, potentially including "pill-in-the-pocket" therapy, warrants further investigation for atrial fibrillation.
  • The REACT-AF trial is poised to offer definitive insights into the optimal anticoagulation strategy for AF management.

Keywords:
anticoagulationatrial fibrillationclinical trials

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.1K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
15
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
809
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
576
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
21
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
17